![Eli Lilly weight loss drug beats Ozempic in head-to-head study](https://www.berlinertageblatt.de/media/shared/articles/46/73/f8/Eli-Lilly-weight-loss-drug-beats-Oz-392108.jpg)
-
Child abuse scandals hang over pope's East Timor visit
-
Manhunt underway in US after Kentucky highway shooting
-
Biden team, end in sight, keeps hope on Gaza truce despite setbacks
-
Sabalenka dedicates US Open to family 'who never gave up' on dream
-
Venezuela takes diplomatic jab at Brazil in spat over election
-
Multiple people shot along highway in US state of Kentucky
-
'Super proud' Sabalenka downs Pegula to win US Open thriller
-
In Papua New Guinea, Pope holds mass 'at the edge of the world'
-
Hewett stays positive for wheelchair tennis despite agonising defeat
-
Three things on US Open champion Aryna Sabalenka
-
Sabalenka downs Pegula to win US Open thriller
-
USA men land Paralympic basketball three-peat, Jiang takes 7th swim gold
-
USA slump to first home defeat against Canada in 67 years
-
Argentina hand Australia record 67-27 loss in Rugby Championship
-
England impress on Carsley bow, Germany, Dutch hit five
-
AFP photographer wins top prize for Gaza coverage
-
No Love for Packers for three weeks after ligament sprain: reports
-
Pedro Almodovar: chronicler of modern Spain crowned in Venice
-
Almodovar wins top Venice prize for end-of-life film
-
Trump sounds dark tone at rally, Harris 'ready' for debate
-
Wirtz and Musiala dazzle to kick-start new Germany era
-
Chinese teenager takes 7th gold of Paris Paralympics
-
England interim boss Carsley 'respects' divided opinions over anthem
-
Neuville moves to the front in the Acropolis Rally
-
Garfield, Pugh charm Toronto in new romance 'We Live in Time'
-
21 boys confirmed dead in Kenya school inferno
-
Over 100,000 protest in France against new prime minister
-
Golden 30 minutes takes China to swimming Paralympics swimming domination
-
Green leads Australia to T20 series sweep of Scotland
-
Nigeria, Cameroon win afer chaotic AFCON build-ups
-
Nicole Kidman: A-lister, cinematic chameleon, wins in Venice
-
'I had to prove myself', says Kolisi after win against All Blacks
-
Almodovar wins top prize at Venice film festival
-
Grealish savours England redemption after 'worst summer'
-
Carsley makes flying start as England interim boss in win over Ireland
-
Springboks close on Rugby Championship with storming win over All Blacks
-
Sri Lanka's De Silva and Kamindu Mendis defy England in third Test
-
Farrell's Racing lose on opening day of Top 14
-
Ireland and UK to 'reset' relations as Starmer visits Dublin
-
Dunbar takes second Vuelta stage as Roglic closes in on victory
-
Fritz eyes US Open glory to end 21 years of American hurt
-
Thousands protest in France against new prime minister
-
Death toll from Kenya school blaze rises to 21
-
Brazil's right rallies for 'freedom' after X suspended
-
Trump to hold rally in swing state, Harris preps for debate
-
Stone at the double as Sri Lanka collapse against England in third Test
-
French tennis player takes legal action over online abuse
-
Italy backs Kyiv's 'legitimate defence' as Zelensky presses allies
-
The Body Shop rescued from administration after deal
-
Martin roars to victory in San Marino sprint, extends MotoGP lead
![Eli Lilly weight loss drug beats Ozempic in head-to-head study](https://www.berlinertageblatt.de/media/shared/articles/46/73/f8/Eli-Lilly-weight-loss-drug-beats-Oz-392108.jpg)
Eli Lilly weight loss drug beats Ozempic in head-to-head study
Patients taking Eli Lilly's new drug Mounjaro achieved significantly greater weight loss than those on Novo Nordisk's Ozempic, a head-to-head study published Monday showed.
Researchers analyzed the electronic health records of more than 18,000 US patients between May 2022 and September 2023 to compare outcomes among those receiving the two medicines, and published the results in JAMA Internal Medicine.
The average age of the patients was 52, more than 70 percent were female, and the average baseline weight was 110 kilograms (242 lbs). Fifty-two percent had type 2 diabetes.
Most patients achieved five percent or greater weight loss after a year, but those on Mounjaro were more likely to lose weight and achieve weight loss.
Overall, nearly 82 percent of the Mounjaro group saw five percent or greater weight loss compared to 67 percent of the Ozempic group.
The results were 62 percent versus 37 percent for 10 percent or greater weight loss, and 42 percent versus 18 percent for 15 percent or greater weight loss, all in favor of Mounjaro.
At 12 months, the average patient on Mounjaro lost seven percent more weight than the average for Ozempic.
No significant differences were noted in the rates of adverse events between the two groups, though discontinuation of the drug was common among both sets of patients.
Ozempic was approved in the United States in 2017, while Mounjaro received approval in 2022.
A global health scourge, obesity is a risk factor for cardiovascular disease, diabetes, certain cancers and complications from diseases such as Covid-19.
Difficult to treat, it is costly for healthcare systems. While its causes can be lifestyle-related, it can also be influenced by genetics.
P.Anderson--BTB